1. Home
  2. DOMH vs THAR Comparison

DOMH vs THAR Comparison

Compare DOMH & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dominari Holdings Inc.

DOMH

Dominari Holdings Inc.

HOLD

Current Price

$3.97

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Logo Tharimmune Inc.

THAR

Tharimmune Inc.

HOLD

Current Price

$2.64

Market Cap

83.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOMH
THAR
Founded
1967
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.0M
83.1M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
DOMH
THAR
Price
$3.97
$2.64
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$17.00
AVG Volume (30 Days)
265.7K
522.9K
Earning Date
11-10-2025
11-12-2025
Dividend Yield
14.10%
N/A
EPS Growth
N/A
N/A
EPS
9.19
N/A
Revenue
$99,588,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.42
N/A
Revenue Growth
691.07
N/A
52 Week Low
$0.83
$0.95
52 Week High
$13.58
$9.08

Technical Indicators

Market Signals
Indicator
DOMH
THAR
Relative Strength Index (RSI) 36.53 47.08
Support Level $3.73 $2.36
Resistance Level $5.00 $2.55
Average True Range (ATR) 0.29 0.20
MACD -0.03 0.01
Stochastic Oscillator 19.22 68.73

Price Performance

Historical Comparison
DOMH
THAR

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: